SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Cacaito who wrote (28664)4/6/1999 9:22:00 PM
From: Abuckatatime  Respond to of 32384
 
Hypothyroidism resolved with discontinuation of bexarotene or with administration of thyroxine. Patients were a mixed group, approx. 2/3s with advanced disease and the other third with early CTCL. High doses (300mg/sq m) were apparently needed to effect disease progression. The authors(Sherman, Gopal, Haugen, et al) state that the results of their trials of bexarotene for CTCL are to be reported later.